Tauroursodeoxycholate (dihydrate)

CAT:
804-HY-19696B-01
Size:
50 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Tauroursodeoxycholate (dihydrate) - image 1

Tauroursodeoxycholate (dihydrate)

  • CAS Number:

    117609-50-4
  • UNSPSC Description:

    Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].
  • Target Antigen:

    Apoptosis; Caspase; Endogenous Metabolite; ERK
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis;MAPK/ERK Pathway;Metabolic Enzyme/Protease;Stem Cell/Wnt
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/tauroursodeoxycholate-dihydrate.html
  • Purity:

    99.86
  • Solubility:

    DMSO : 83.33 mg/mL (ultrasonic)
  • Smiles:

    C[C@H](CCC(NCCS(=O)(O)=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C.O.O
  • Molecular Weight:

    535.73
  • References & Citations:

    [1]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.|[2]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    Launched